An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor.
about
siRNA Versus miRNA as Therapeutics for Gene SilencingCytokines as biomarkers of nanoparticle immunotoxicityLipid-based vectors for siRNA deliveryNanomedicine in pulmonary deliveryBiodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery.Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes.Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting.Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.Triple-responsive expansile nanogel for tumor and mitochondria targeted photosensitizer delivery.Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid TumorsNanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy.Gene Silencing of Human Neuronal Cells for Drug Addiction Therapy using Anisotropic NanocrystalsAnti-tumor activity of splice-switching oligonucleotides.Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.Co-delivery of small interfering RNA and plasmid DNA using a polymeric vector incorporating endosomolytic oligomeric sulfonamide.More effective nanomedicines through particle designTrp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model.Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumorBiocompatible and colloidally stabilized mPEG-PE/calcium phosphate hybrid nanoparticles loaded with siRNAs targeting tumors.Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers.Polymeric nucleic acid carriers: current issues and novel design approachesSystemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy.Preparation of optimized lipid-coated calcium phosphate nanoparticles for enhanced in vitro gene delivery to breast cancer cellsPolyMetformin combines carrier and anticancer activities for in vivo siRNA delivery.Reiterated Targeting Peptides on the Nanoparticle Surface Significantly Promote Targeted Vascular Endothelial Growth Factor Gene Delivery to Stem Cells.Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice.Endothelial glycocalyx conditions influence nanoparticle uptake for passive targeting.Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery.Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis.A Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression In VivoShell-crosslinked knedel-like nanoparticles induce lower immunotoxicity than their non-crosslinked analogs.Nonviral methods for siRNA deliveryDifferential immunotoxicities of poly(ethylene glycol)- vs. poly(carboxybetaine)-coated nanoparticles.Targeted delivery systems for oligonucleotide therapeutics.Lipid-based systemic delivery of siRNA.Effect of inserted spacer in hepatic cell-penetrating multifunctional peptide component on the DNA intracellular delivery of quaternary complexes based on modular design.Lipidic systems for in vivo siRNA delivery.Bioengineered nanoparticles for siRNA delivery.Nanostructured hyaluronic acid-based materials for active delivery to cancer.In vivo gene delivery by nonviral vectors: overcoming hurdles?
P2860
Q26786876-6D97D59A-70DB-4247-AB75-7D6044C827CAQ28383550-054D14DA-C91F-4FCC-8C70-1C87839BE341Q28828356-7F6D706F-DCCE-4300-80C6-C0D4F85D23AEQ33572981-C61DF4D9-4C16-490D-8EB8-B63EAFE4B5E1Q33708084-BB047FEB-B5CF-42C3-B788-FAEA7F858CFAQ33811463-CEFD0BD9-DF63-444D-A34A-044E1C1FDE6EQ33987573-A983ECCA-64C9-45C5-A0F3-B4E0F3BEE181Q34025149-EAEE854F-C5EB-42BC-8723-4D7BCFE79444Q34146404-E72BEC35-2B0C-422B-8848-9913945CE796Q34165321-20E6A391-0726-4ECC-93F8-9AA43A175C14Q34209735-2D8F3537-3A0B-432F-970C-03803FBA13BCQ34381259-AECF5845-2938-4033-9636-6D8966568274Q34401490-4549C626-57A7-4BD0-A17D-1BACCB235B1FQ34874835-16901AC4-4897-4627-B029-1E31CE8369F2Q34984827-FC39331B-D051-4BC6-9707-2E9F22C30488Q35106115-AAA7E21E-EBDA-4DF7-98CA-DFF91F9A4687Q35739956-A8053B8C-3D11-4871-8646-DB66656D033EQ35785890-58657EF6-D239-4473-B356-EB97D17FA556Q35857347-76130140-0409-4526-BC71-4B9049B17CE3Q35903717-28C3E4FA-497D-4376-8098-64A940426AC6Q36413210-8CCA4C26-D013-456A-AA5E-5B396A84DCAAQ36673747-AE2EEEA7-7666-4C1B-A71B-A41AC6DF0498Q36907352-9D7FD7E8-1E2E-4B0C-9879-76266D956C00Q36980520-5F7B58A1-3A40-41CC-B3C9-A4A2247998CEQ37041753-AD8170EC-C5DF-45EE-8D13-97877751E0B0Q37111373-FB2DE003-035A-412E-ACC1-829E7E599B76Q37123290-96AFC0C4-9BAE-47E6-8EFE-680F9E34ACC5Q37251480-615D0F6C-F7BB-41EB-8E64-8F383A95D530Q37254863-21881632-62B3-4591-90E0-699A2934FBF2Q37258262-9AC04F29-0A62-430D-AEF9-56D9711A09C2Q37265121-38CF71CC-7F2D-4470-8D79-4352EE8E4834Q37360226-91257457-2B27-4CC3-AA6D-32159D195E97Q37381547-2B5F7339-53E6-43ED-887E-26EA7501E5F0Q37417572-E2839938-D190-400A-A799-8C2BADB1F2F5Q37425606-92728B21-4B0F-42A0-ABC0-A28ABACA1206Q37446978-E7DA0C7F-D81F-4CEC-9833-90585E423A82Q37598096-FB8A5382-9BB6-4F24-AF43-5E57DCFD70BFQ37679156-65E73C23-C599-41DC-A1EC-99E6B1C05473Q37724371-E19E9A41-05BC-466C-A032-07339C93B050Q38004708-49E8AF84-79B8-4005-83D2-FB7F7A58FC31
P2860
An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
An efficient and low immunosti ...... c siRNA delivery to the tumor.
@en
type
label
An efficient and low immunosti ...... c siRNA delivery to the tumor.
@en
prefLabel
An efficient and low immunosti ...... c siRNA delivery to the tumor.
@en
P2093
P2860
P1476
An efficient and low immunosti ...... c siRNA delivery to the tumor.
@en
P2093
Christine C Conwell
Leaf Huang
Shyh-Dar Li
Sumio Chono
P2860
P356
10.1016/J.JCONREL.2008.07.006
P407
P577
2008-07-13T00:00:00Z